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ABSTRACT
Context: There is an unmet need to discover new treatments for Alzheimer’s disease. This study deter-
mined the anti-acetylcholinesterase (AChE) activity, DPPH free radical scavenging and antioxidant proper-
ties of Carpolobia lutea G. Don (Polygalaceae).
Objective: The objective of this study is to quantify C. lutea anti-AChE, DPPH free radical scavenging, and
antioxidant activities and cell cytotoxicity.
Materials and methods: Plant stem, leaves and roots were subjected to sequential solvent extractions,
and screened for anti-AChE activity across a concentration range of 0.02–200lg/mL. Plant DPPH radical
scavenging activity, reducing power, and total phenolic and flavonoid contents were determined, and
cytotoxicity evaluated using human hepatocytes.
Results: Carpolobia lutea exhibited concentration-dependent anti-AChE activity. The most potent inhibi-
tory activity for the stem was the crude ethanol extract and hexane stem fraction oil (IC50¼ 140lg/mL);
for the leaves, the chloroform leaf fraction (IC50¼ 60lg/mL); and for roots, the methanol, ethyl acetate
and aqueous root fractions (IC50¼ 0.3–3lg/mL). Dose-dependent free radical scavenging activity and
reducing power were observed with increasing stem, leaf or root concentration. Total phenolic contents
were the highest in the stem: 632mg gallic acid equivalents/g for a hexane stem fraction oil. Total fla-
vonoid content was the highest in the leaves: 297mg quercetin equivalents/g for a chloroform leaf frac-
tion. At 1lg/mL, only the crude ethanol extract oil was significantly cytotoxic to hepatocytes.
Discussion and conclusions: Carpolobia lutea possesses anti-AChE activity and beneficial antioxidant cap-
acity indicative of its potential development as a treatment of Alzheimer’s and other diseases character-
ized by a cholinergic deficit.
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Introduction
Alzheimer’s disease (AD) is the most prevalent neurodegenerative
disease; with symptomology that typically includes confusion,
memory loss, impaired cognitive and emotional function, and
dementia. In 2015, the number of people living with dementia
was estimated to be 46.8 million, with an associated economic
burden of 818 billion US dollars (Alzheimer’s Disease
International 2015). The pathological hallmarks of AD are the
deposition of extracellular amyloid plaques composed of insol-
uble amyloid beta (Ab) peptides and intra-neuronal neurofibril-
lary tangles (NFTs) of hyperphosphorylated Tau protein.
Collectively, these peptide and protein accumulations are thought
to be toxic to neuronal tissue and contribute to the neuronal
death and cerebral atrophy observed in AD patients (Parihar and
Hemnani 2004; Ballard et al. 2011).
The aetiopathology of AD is complex and heterogeneous due
to multifaceted disease mechanisms. These include mitochondrial
dysfunction, redox and inflammatory stress, and alteration of
neurotransmitter activities including cholinergic dysfunction
(Parihar and Hemnani 2004; Mufson et al. 2008; Ballard et al.
2011). Acetylcholine signalling is terminated within the synaptic
cleft through cleavage by acetylcholinesterase (AChE). Hence,
drugs that mimic acetylcholine activity (cholinomimetics), or
drugs that limit acetylcholine breakdown (AChE inhibitors) have
provided a therapeutic strategy to augment cholinergic signalling
in AD patients (Seltzer 2006; Mufson et al. 2008; Ballard et al.
2011; Sun et al. 2012).
Physostigmine (eserine), tacrine, rivastigmine, donepezil, gal-
antamine and huperzine A are drugs that have been employed
for symptomatic treatment of AD. Their mode of action is pri-
marily through inhibition of AChE to limit the cholinergic deficit
(Sun et al. 2012). However, a search continues for other anti-
AChE drugs that temper AD progression, but without induction
of unwanted side effects.
Globally, natural products and secondary metabolites are uti-
lized in traditional or alternative medicines. Herbal medicines,
particularly Chinese and Indian traditional medicines, have for
many centuries been specifically utilized to restore declining
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cognitive functions (Howes and Houghton 2003; Gurib-Fakim
2006; Adams et al. 2007; Shiksharthi et al. 2011). Medicinal
plants may possess an array of secondary metabolites such as
polyphenols and flavonoids with broad-spectrum pharmaco-
logical activities including cellular antioxidant activities capable
of scavenging damaging free radicals. Indeed, the mechanism by
which medicinal plants are able to induce therapeutic effects in
AD patients may be diverse and include anti-amyloid production,
anti-apoptotic, antioxidant and anti-inflammatory activities, in
addition to targeting cholinergic deficits (Howes and Houghton
2003; Anekonda and Reddy 2005; Akhondzadeh and Abbasi
2006; Adams et al. 2007; Mukherjee et al. 2007; Hajiaghaee and
Akhondzadeh 2012; Orhan 2013; Ansari and Khodagholi 2013;
Menon et al. 2013; Shakir et al. 2013; Syad and Devi 2014).
Furthermore, herbal drugs may be less toxic, display improved
blood–brain barrier penetrance and exhibit beneficial synergistic
effects when compared with single moiety synthetic drugs.
Systematic in vitro and in vivo screening of natural plant
extracts and fractions will potentially provide new active material
able to treat AD and other cognitive dysfunctions. Carpolobia
lutea G. Don (Polygalaceae) is a perennial shrub native to West
and Central Tropical Africa. It is widely distributed in rainforests
and the Guinea savannah of Sierra Leone, Cameroon and
Nigeria. Extracts and fractions of C. lutea have hitherto only
been reported anecdotally to possess benefits to cognition, with
the study of C. lutea that has included an examination of its anti-
diarrheal (Nwidu, Essien et al. 2011), anti-nociceptive (Nwidu,
Nwafor et al. 2011) and gastro-protective effects (Nwidu et al.
2014). Herein extracts and fractions of the stem, leaves and roots
of C. lutea were scrutinized for therapeutic promise as an AD
treatment via their ability to inhibit AChE. Additionally, extracts
and fractions were examined for radical scavenging and reducing
(antioxidant) activities, polyphenol and flavonoid contents deter-
mined, and C. lutea cytotoxicity was also assessed.
Materials and methods
Materials
All chemicals were purchased from Sigma Aldrich (Irvine, UK)
unless specified otherwise.
Preparation of plant material
Plant leaves, stem and roots from Carpolobia lutea grown in the
wild were collected in January 2015 from Itak Ikpa village in the
Ikono Local Government Area of Akwa Ibom State, Nigeria.
Plant parts were supplied by Mr. Okon Etefia, a traditional herb-
alist, attached to the Pharmacognosy Department, University of
Uyo, Nigeria. Plant identification was authenticated by Dr.
Margaret Bassey, Department of Botany, University of Uyo,
Nigeria. A voucher specimen (UUH 999) was deposited at the
University Herbarium, University of Uyo, Nigeria. Plant parts
were air-dried under shade for 2 weeks at 30 C and then pow-
dered with a hammer mill. The pulverized material was stored at
room temperature until required.
Extraction of leaf, stem-bark and root of C. lutea
A flow chart depicting the complete preparation of plant extracts
and fractions from C. lutea is included in Supplementary
Figure S1.
Powdered leaves (750 g) were subjected to sequential extrac-
tion by maceration for 72 h in 2.5 L of n-hexane to obtain the
n-hexane fraction (n-HLF). The marc was air-dried and the pro-
cedure repeated with chloroform, ethyl acetate, and then ethanol
solvents to obtain the corresponding chloroform leaf fraction
(CHLF), ethyl acetate leaf fraction (EALF) and ethanol leaf frac-
tion (ETLF), respectively, by filtration and concentration under
reduced pressure by the use of rotary evaporation at 40 C.
The crude ethyl acetate leaf extract (cEALE), crude ethanol
leaf extract (cETLE), crude ethanol stem-bark extract (cETSE)
and crude methanol root extract (cMTRE) were obtained after
72 h of maceration in each respective solvent, and filtered and
concentrated under reduced pressure as above.
A hot aqueous leaf extract (HALE) and hot aqueous stem-
bark extract (HASE) were obtained by the addition of 1 L of
boiling water to 500 g of the powdered leaf or stem-bark mater-
ial, shaking for 1min and then the material allowed to stand for
60min. Solvent extracts were filtered and the process repeated
after 24 h. The marc obtained from the leaf extract was dried to
a constant weight after 48 h at 50 C. The residue remaining was
immersed in 1 L of butanol for 72 h after which it was processed
as above to yield a crude butanol leaf extract (cBULE). The yield
obtained for each extract is listed in Table 1.
Fractionation of stem-bark and root of C. lutea
The crude ETSE of C. lutea (60 g) was divided into four equal
aliquots, and then further fractionated by mixing with 60 g of sil-
ica gel. This material was placed in a glass column and eluted
sequentially, under pressure, with 500mL each of n-hexane,
dichloromethane, ethyl acetate and then methanol to obtain the
corresponding fractions: n-hexane stem fraction (n-HSF),
dichloromethane stem fraction (DCSF), ethyl acetate stem frac-
tion (EASF) and methanol stem fraction (MTSF), respectively.
Table 1. Percentage yield, AChE and DPPH radical scavenging IC50 concentra-
tions of stem, leaf, and root extracts and fractions of C. lutea.
Extract or fraction Yield (%)
IC50 concentration (lg/mL)
AChE
DPPH radical
scavenging
Stem
cETSE 21.7 140 343
EASF 1.75 472 675
n-HSF oil 22.0 140 >1000
EASF oil 9.0 503 123
n-HSF 19.1 912 >1000
MTSF 52.8 142 118
MTSF oil 12.9 472 825
cSSE 22.0 811 351
DCSF 19.5 >1000 449
cETSE oil 15.6 840 334
HASE 12.5 547 504
Leaf
cHALE 13.4 >1000 196
cETLE 7.8 478 849
CHLF 3.0 60 500
cETLF 27.1 81 >1000
cBULE 10.2 738 >1000
n-HLF 3.7 461 141
cEALE 3.6 500 >1000
Root
cMTRE 44.1 3 509
CHRF 12.3 137 849
BURF 8.0 247 >1000
n-HRF 16.5 173 500
EARF 5.8 0.3 >1000
AQRF 20.2 2 141
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The same procedure was followed to fractionate 15 g of crude
ethanol stembark extract oil (cETSE oil), n-hexane stem fraction
oil (n-HSF oil), ethyl acetate stem fraction oil (EASF oil) and
methanol stem fraction oil (MTSF oil). The fractions obtained
were reduced in volume using rotary evaporation before drying
under nitrogen flow. Thereafter, the extracts were stored in an
airtight container at 4 C until required. HASE was subjected to
further sequential extraction with n-hexane, ethyl acetate and
butanol, but only the ethyl acetate fraction of HASE yielded sig-
nificant material for use.
To prepare the crude methanol root extract (cMTRE), 50 g
was mixed with 100 g silica gel and placed in a glass column and
sequentially eluted with n-hexane (n-hexane root fraction
[n-HRF]), chloroform (chloroform root fraction [CHRF]), ethyl
acetate (ethyl acetate root fraction, EARF), butanol (butanol root
fraction, BURF)) and aqueous fractions (aqueous root fraction,
AQRF). The dry weight of each fraction was obtained after com-
plete evaporation of the solvent in a fume cupboard. Extracts
and fractions were stored at 4 C until use. Each extract or frac-
tion was reconstituted in pure (milli Q) water before use in
experimental assays.
Preparation of crude saponins
From the hot aqueous stem extract (HASE), a crude saponin
stem extract (cSSE) was prepared. A portion of HASE, weighing
5 g, was transferred to a conical flask and soaked with 25mL of
20% methanol. The mixture was heated for 12 h at constant tem-
perature of 55 C with stirring. Thereafter, it was filtered and
material extracted with 60mL of 20% methanol. The volume of
the liquid extracted was reduced to 30mL using a water bath
and transferred to a separating funnel. Diethyl ether (40mL) was
added, and, after vigorous shaking, the organic layer was
removed and retained. n-Butanol (60mL) was added to the aque-
ous fraction. The combined aqueous-butanol mixture was washed
with 5% NaCl solution, before evaporation of the solvents in a
fume cupboard using a water bath to yield crude saponins.
Once prepared all extracts were stored at 4 C, with experi-
mental assays performed within a 4-month period.
Animals
For rat brain AChE measurements, male F344 strain rats weigh-
ing between 200 and 230 g were used for experiments. Rats were
maintained in cages under controlled temperature (21 ± 1 C) and
light (16 h light/8 h dark cycle) with ad libitum access to food
intake and water. All animal procedures were approved by the
University of Nottingham Local Ethical Review Committee (study
reference CHE 10) and were carried out in accordance with the
Animals Scientific Procedures Act (UK) 1986.
AChE activity assay
AChE activity was measured based on the method of Ellman
et al. (1961), adapted for a microtitre plate format. Briefly, for
each assay data point, 50 lL of 3mM 5,50-dithiobis-(2-nitroben-
zoic acid) (DTNB), 50 lL of recombinant AChE (1mg/mL)
(Sigma, C3389, Irvine, UK) or rat brain homogenate (prepared at
10% (w/v) according to Carter et al. (2007) and Tarhoni et al.
(2011), 35 lL of 50mM Tris/HCl pH 8.0 and 40 lL of plant
extract or fraction was mixed and incubated at 37 C. The assay
was initiated by the addition of 25 lL of 15mM
acetylthiocholineiodide (ATCI), with production of 5-thio-2-
nitrobenzoate anion read at 412 nm every 5 s for 10min using a
Spectramax microplate reader (ThermoFisher, Stafford, UK).
Assay reactions with plant extracts or fractions were all per-
formed in triplicate at concentrations of 200, 20, 2, 0.2 and
0.02 lg/mL. A negative control assay performed in the absence of
AChE provided a reagent blank. Eserine (Sigma, E8375, Irvine,
UK) or the organophosphate pesticide, azamethiphos-oxon
(QMX Laboratories Ltd, Thaxted, UK), was used as a positive
control to inhibit electric eel or rat brain AChE in a dose-
dependent fashion (Supplementary Figure S2). The percentage
inhibition of AChE by plant extracts or fractions was calculated
relative to inhibition by eserine, with the plant extract or fraction
concentration producing 50% inhibition (IC50) of AChE
determined.
2,2-Diphenyl-1-picrylhydrazyl (DPPH) radical scavenging
activity
Stock solutions of extracts or fractions (5mg/mL) were diluted to
final concentrations of 200, 100, 50, 25, 12.5 and 6.25lg/mL in
ethanol. One hundred and sixty microlitre of 0.1mM DPPH in
ethanol was added to 20 lL of extract or fraction, or vitamin E
(as a positive control), and the material mixed with 20 lL of
water. A control solution of b-tocopherol was also assayed over a
concentration range of 1.56, 0.78, 0.39, 0.195 and 0.0975mg/mL.
The mixture was incubated at 37 C for 40min in the dark,
before reading the absorbance at 517 nm using a Spectramax
microplate reader (ThermoFisher, Stafford, UK). Experimental
blanks were performed in the absence of extracts or fractions.
The percentage antioxidant activity was estimated as the percent
DPPH radical scavenging activity. All tests were performed in
triplicate and inhibition percentages reported as means ± SD.
Reducing power assessment
The reducing power of plant extracts or fractions was assessed as
the ability to reduce ferric iron (Fe3þ) to ferrous iron (Fe2þ).
Concentrations of plant extracts or fractions were prepared
across a concentration range of 6.25–50 lg/mL. Aliquots of 4 lL
of 5mg/mL of each plant sample were added to 400lL of phos-
phate buffer pH 7.4 and 250 lL of 1% potassium ferricyanide
and incubated at 50 C for 20min. Then 250lL of 10% trichloro-
acetic acid was added, and after mixing, samples were centrifuged
at 3000 rpm for 10min. One hundred microlitres of the super-
natant was mixed with a similar volume of water and added to a
microtiter plate well. Freshly prepared ferric chloride solution
(20 lL) was added, and the formation of Perls’ Prussian blue fol-
lowed at 700 nm using a Spectramax plate reader (ThermoFisher,
Stafford, UK). A blank was prepared without addition of antioxi-
dant. All assay points were conducted in triplicates. L-Ascorbic
acid was used as a positive control antioxidant. The percentage
increase of reduction activity to that of control for plant extracts
and fractions, and percentage of ascorbic acid reducing capacity
were calculated.
Determination of total phenolic content
Total phenolic content was determined using the
Folin–Ciocalteau reagent (FCR) method as described in a previ-
ous publication (Nwidu et al. 2012). Plant extract (20 lL) or frac-
tion (20 lL) (a concentration range of 1–100lg/mL) was mixed
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with 90 lL of water, followed by the addition of 30 lL of FCR
and vigorous shaking on a plate reader. Within 8min, 60 lL of
7.5% Na2CO3 solution was added and the material incubated at
40 C in a shaking incubator. After 40min, the mixture was read
in a spectrophotometer at 760 nm. Gallic acid (Sigma,
CAS14991-7, Irvine, UK) was similarly processed over a concen-
tration range of 0.1–0.5mg/mL as a positive control, and used to
generate a calibration curve for quantification of total phenolic
content in extracts and fractions across the concentration range
of 0.01–0.05mg/mL. Total phenolic content was expressed as mg
gallic acid equivalents/gram of plant extract or fraction (mg
GAE/g).
Determination of total flavonoid content
Total flavonoid content of plant extracts was determined using
quercetin as a reference compound. Briefly, 20 lL of plant extract
(5mg/mL) in ethanol was mixed in a microtiter plate well with
200lL of 10% aluminium chloride solution and 1M potassium
acetate solution. The mixture was incubated for 30min at room
temperature before reading the absorbance at 415 nm using a
Spectramax plate reader (ThermoFisher, Stafford, UK). Total fla-
vonoid content of plant extracts or fractions was determined as
mg quercetin equivalents/gram of extract or fraction (mg QUER
equivalent/g).
Cell culture
Human hepatocellular carcinoma (HepG2) cells from the ATCC
collection were cultured in Eagles’s minimum essential media
(EMEM) with 2mM glutamine, 1% non-essential amino acids
(NEAA), 10% foetal bovine serum (FBS) and antibiotics (100 lg/
mL penicillin and 100lg/mL streptomycin). Cells were grown in
a humidified atmosphere at 37 C and 5% CO2.
Cytotoxicity assays
Cells were seeded at 3 104 cells per well in 96-well plates. At
80–90% confluence, extracts or fractions of C. lutea were added
to wells at 0.1, 1, 10 and 100 lg/mL. After a 48 h treatment,
media were removed and cells were incubated with fresh medium
containing 0.5% thiazolyl blue tetrazolium bromide (MTT)
reagent (Sigma, M2128, Irvine, UK). After 4 h at 37 C in the
humidified incubator, the media were replaced with 100lL of
isopropanol and DMSO solution [1:1 (v/v)] and the absorbance
was read at 540 nm in a Spectramax plate reader (ThermoFisher,
Stafford, UK). Each assay point was conducted in triplicate.
Control assays performed in the absence of extract/fractions, and
with extracts/fractions and in the absence of cells, were sub-
tracted from absorbance values. The percentage of cells surviving
was calculated for each concentration of C. lutea extract or
fraction.
Statistical analysis
All statistical procedures were performed using PRISM 5
(GraphPad Software Inc., San Diego, CA). IC50 values were cal-
culated using non-linear regression analysis. One-way ANOVA
test with Dunn’s multiple comparisons post-test were used for
comparisons of different group’s data. Results were expressed as
means ± SD. Statistical significance was defined as p< 0.05.
Results
Carpolobia lutea extracts display AChE inhibitory activity
Carpolobia lutea stem-bark, leaf and root extracts inhibited
AChE activity in a dose-dependent manner (Figures 1(A–C)). At
the highest dose assessed (200 lg/mL), the EASF oil and cSSE
(Figure 1(A)); CHLF (Figure 1(B)); and BURF, n-HRF, and
AQRF (Figure 1(C)) inhibited AChE to 90–100% of that
observed using 0.02 lg/mL eserine. From these five assay con-
centrations (0.02–200lg/mL), an approximate IC50 concentration
was calculated. The roots were observed to retain the highest
inhibitory potency (lowest IC50 concentrations) (Table 1).
The descending order of AChE inhibitory activity for the
stem extracts and fractions was cETSE and n-HSF
oil>MTSF>EASF, MTSF oil>EASF oil>HASE> cSSE>
cETSE oil> n-HSF>DCSF. For the leaves, the descending order
of AChE inhibitory potency was CHLF> cETLF> n-
HLF> cETLE>EALF> cBULE> cHALE; and for the roots
EARF>AQRF> cMTRE>CHRF> n-HRF>BURF.
Carpolobia lutea extracts display DPPH scavenging activity
Carpolobia lutea stem, leaf and root extracts and fractions exhib-
ited DPPH radical scavenging activity in a concentration-depend-
ent manner (Figures 2(A–C)). The quantitation of DPPH radical
scavenging ability across the concentration range of
62.5–1000lg/mL was used to calculate IC50 concentrations
(Table 1). The MTSF, n-HLF and AQRF displayed the most
potent DPPH radical scavenging activity (lowest IC50s) for the
stem, leaves and roots, respectively (Table 1). Collectively, for the
stem, the descending order of DPPH radical scavenging activity
was the following: MTSF>EASF oil> cETSE oil>
cETSE> cSSE>DCSF>HASE>EASF>MTSF oil> n-HSF, n-
HSF oil (Table 1). For the leaves, DPPH radical scavenging activ-
ity was in the descending order: n-HLF> cHALE>
CHLF> cETLE> cBULE, EALF, cETLF; and for the roots:
AQRF> n-HRF> cMTRF>CHRF>EARF, BURF.
Carpolobia lutea extracts display reducing (antioxidant)
activity
Carpolobia lutea stem, leaf and root extracts and fractions dis-
played reducing (antioxidant) capacity in a concentration-
dependent fashion (Figures 3(A–C)). Some extracts and fractions
of stem and leaves displayed no reductive capacity, or indeed
were oxidative in nature (values below zero) for concentrations of
6.25–25lg/mL. At the highest concentration examined (50lg/mL),
the reducing capacity of the stem extracts and fractions was
DCSF>EASF oil> cSSE>EASF> cETSE>ETSE oil>HASE>
MTSF>MTSF oil> n-HSF oil> n-HSF (Figure 3(A)). Notably the
DCSF had a higher percentage reducing capacity than
the assayed standard, ascorbic acid (vitamin C). At 50 lg/mL,
the reducing capacity of the leaf extracts and fractions
was cHALE>EALF> cETLE>CHLF> n-HLF>ETLF> cBULE
(Figure 3(B)). For the root extracts and fractions, the order was
BURF>EARF>AQRF>MTRE> n-HRF>CHRF. Collectively,
the roots displayed the greatest reducing capacity, with both
BURF and EARF possessing comparable reductive capacity to
vitamin C.
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Figure 1. AChE inhibitory activity of plant extracts and fractions of C. lutea. Plant inhibition of AChE was measured using a modified Ellman assay, with percentage
inhibition of AChE calculated relative to eserine. (A) Stem, (B) leaf and (C) root. Results are expressed as means ± SEM for three separate experiments at each
concentration.
Figure 2. DPPH radical scavenging activity of plant extracts and fractions of C. lutea. Plant antioxidant activity was assessed via the percent inhibition (radical scaveng-
ing) of DPPH. Vitamin E was used as a positive control. (A) Stem, (B) leaf, and (C) root. Results are expressed as means ± SEM for three separate experiments at each
concentration.
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Total phenolic and total flavonoid content of C. lutea
The total phenolic content measured as mg gallic acid equiva-
lents/gram and total flavonoid content measured as mg quercetin
equivalents/gram were determined for each extract and fraction
(Table 2). For the stem, the n-HSF oil and the DCSF possessed
the highest total phenolic content. The total phenolic
content decreased in the following order: n-HSF
oil>DCSF> cETSE>MTSF> n-HSF> cETSE oil>HASE>
EASF>MTSF oil> cSSE>EASF oil. Similarly, the n-HSF oil
possessed the highest total flavonoid content,; with a descending
order of n-HSF oil> n-HSF>MTSF oil>EASF> cSSE> cETSE
oil> cETSE>EASF oil>DCSF>HASE>MTSF.
For the leaves, the total phenolic content was cBULE> n-
HLF> cETLE> cHALE>CHLF> cETLF> EALF; and, for total
flavonoid content, CHLF> n-HLF>EALF> cETLF> cETLE>
cBULE> cHALE.
For the roots, the total phenolic content was BURF> n-
HRF>EARF> cMTRE>CHRF>AQRF; and, for total flavonoid
content, BURF> n-HRF>CHRF>EARF>AQRF> cMTRE.
Assessment of C. lutea cytotoxicity
Carpolobia lutea stem, leaf or root extracts and fractions were
evaluated for cytotoxicity to human liver HepG2 cells over a
broad concentration range of 0.1–100 lg/mL. Evaluation of cyto-
toxicity included extracts/fractions of relatively potent AChE
inhibitory activity (cETSE, n-HSF Oil, MTSF, cMTRE, CHRF,
EARF), DPPH radical scavenging activity (MTSF, cHALE) and
high phenolic content (n-HSF Oil, DCSF). At the highest
dose employed, HepG2 cell viability was still 100% with some
of the stem (cETSE, n-HSF Oil, MTSF, MTSF Oil) and root
(cMTRE, EARF) extracts/fractions, with IC50s of>2000lg/mL
(Table 3). However, certain stem (EASF, n-HSF, DCSF, cETSE
Oil, HASE), leaf (cHALE) or root (CHRF) extracts/fractions dis-
played dose-dependent inhibition of cell viability albeit with rela-
tively high IC50 values (691 to>2000lg/mL). Interestingly,
incubation of cells with several plant extracts/fractions (cETSE,
MTSF, cBULE, cMTRE, EARF) at concentrations of 0.1–10 lg/
mL triggered a significant increase of cell metabolic activity with
MTT assay results above 100% (Table 3).
Discussion and conclusions
The prevalence of neurodegenerative disease is increasing due to
an ever ageing population, with the number of individuals living
with dementia expected to double every 20 years, reaching 74.7
million by 2030 (Alzheimer’s Disease International 2015). The
World Health Organization has recognized this as a global
healthcare problem of potentially epidemic proportion (Global
Health and Aging report 2011). Treatment of neurodegenerative
diseases such as AD is currently limited, and new medicines that
alleviate symptomology and restrict disease progression are
required.
An ethnopharmacological approach of systematic screening of
natural products is a cost effective strategy of developing novel
drug treatments. Indeed, rivastigmine and galantamine are FDA-
approved AChE inhibitors that were derived from medicinal
plants, and are utilized for the treatment of mild to moderate
AD (Mu~noz-Torrero 2008; Ballard et al. 2011; Syad and Devi
2014). Our screening study demonstrated that extracts and frac-
tions of the stems, leaves and roots of C. lutea inhibit AChE in a
dose-dependent fashion. The cETSE, MTSF and n-HSF oil from
Figure 3. Reductive capacity of plant extracts or fractions of C. lutea. Plant reducing power was assessed via the ability to reduce ferric (Fe3þ) to ferrous (Fe2þ) iron.
The percentage increase of reductive capacity with increasing plant extract concentration was determined. Ascorbic acid (vitamin C) was used as a positive control. (A)
Stem, (B) leaf, and (C) root. Results are expressed as means± SEM for three separate experiments at each concentration.
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the stem-bark were approximately equipotent at inhibiting AChE
with IC50 values of 140lg/mL. Two leaf fractions, CHLF and
ETLF, exhibited even lower IC50 values of 60 and 81lg/mL,
respectively. For roots, the AQRF, EARF and MTRE were the most
potent inhibitors of AChE, with IC50 values of 0.3–3.0 lg/mL.
Pure eserine (physostigmine) at 0.02lg/mL (72 nM) was
employed as a positive control in our assays. At this concentra-
tion, eserine was able to inhibit electric eel AChE to approaching
100% (results not included), and likewise inhibit rat brain AChE
(Supplementary Data Figure S2). Human brain AChE should also
be inhibited to approaching 100% at this eserine concentration
(IC50 of 14 nM) (Thomsen et al. 1991; Triggle et al. 1998).
Hence, root extracts of C. lutea show particular promise for pro-
vision of a useful AChE inhibitor since in a partially purified
state their IC50 was only an order of magnitude less potent than
eserine. By comparison, the anti-AChE drug tacrine has an IC50
value of 1 lM against human AChE (Thomsen et al. 1991),
approximately 72 times less potent than eserine.
In addition to notable AChE inhibitory activity, our study
also highlights the existence and activity of C. lutea secondary
metabolites. Carpolobia lutea contains polyphenols and flavo-
noids (Table 2), compounds that exhibit scavenging (antioxidant)
activities. These antioxidants may counter free radical damage
produced during metabolism and for which radical levels may be
exacerbated in AD (Parihar and Hemnani 2004; Zhao and Zhao
2013). For comparison to standards, the majority of stem and
root extracts/fractions at a 1mg/mL concentration displayed
DPPH free radical scavenging ability comparable with vitamin E
(Figures 2(A,C)). Likewise, reductive (antioxidant capacity) of
certain stem (EASF oil, cSSE, DCSF) and root (BURF, EARF)
extracts/fractions at 50 lg/mL was comparable with vitamin C
(ascorbic acid) (Figures 3(A,C)). The majority of leaf extracts/
fractions were relatively weak DPPH radical scavengers, in keep-
ing with a previous preliminary screening of C. lutea leaves
(Nwidu et al. 2012). At concentrations of 6.25–25 lg/mL, some
of the stem and leaf extracts of C. lutea were oxidative in nature
(Figure 3(A,B)), indicative of the presence of pro- as well as anti-
oxidant chemicals.
There is a growing list of plants that have similarly been
screened for anti-AChE activity and that also possess beneficial
natural antioxidants (secondary metabolites) that can comple-
ment endogenous antioxidant systems (Mukherjee et al. 2007;
Calderon et al. 2010; S¸enol et al. 2010; Hlila et al. 2013;
Natarajan et al. 2013; Syad and Devi 2014). By comparison with
these, C. lutea roots exhibit sub-micromolar IC50 values and are,
therefore, among the more potent phytochemical inhibitors of
AChE (Natarajan et al. 2013; Pinho et al. 2013; Tundis et al.
2016).
Some plant constituents are also able to inhibit butyrylcholi-
nesterase (BChE) in vitro (Pinho et al. 2013; Tundis et al. 2016).
The AD drug rivastigmine is a weak inhibitor of both AChE and
BChE in vitro (Pinho et al. 2013), but in vivo, the AD drugs
huperzine A and donepezil specifically inhibit AChE rather than
BChE (Duysen et al. 2007), and similarly, in vitro, AChE displays
a 1000-fold higher affinity than BChE to inhibition by huperzine
A (Ashani et al. 1992). It has been suggested that BChE activity
Table 2. Total phenolic and total flavonoid content of stem, leaf and root
extracts and fractions of C. lutea.
Extract or fraction
Total phenolic
content (mg GAE/g)
Total flavonoid content
(mg QUER E/g)
Stem
cETSE 235.33 ± 0.01 30.59 ± 0.01
EASF 177.23 ± 0.01 100.37 ± 0.20
n-HSF oil 632.28 ± 0.00 196.21 ± 0.10
EASF oil 3.00 ± 0.00 29.54 ± 0.20
n-HSF 226.46 ± 0.00 176.87 ± 0.20
MTSF 234.99 ± 0.02 1.75 ± 0.01
MTSF oil 128.42 ± 0.01 116.49 ± 0.04
cSSE 26.0 ± 0.00 78.72 ± 0.30
DCSF 581.49 ± 0.00 19.59 ± 0.01
cETSE oil 198.50 ± 0.00 40.85 ± 0.01
HASE 178.37 ± 0.00 11.94 ± 0.02
Leaf
cHALE 256.04 ± 0.01 17.04 ± 0.00
cETLE 257.02 ± 0.02 24.69 ± 0.02
CHLF 144.67 ± 0.01 296.68 ± 0.03
cETLF 120.32 ± 0.01 63.28 ± 0.02
cBULE 292.29 ± 0.01 19.21 ± 0.00
n-HLF 285.63 ± 0.00 246.22 ± 0.20
cEALE 100.85 ± 0.00 118.23 ± 0.00
Root
cMTRE 246.28 ± 0.00 9.36 ± 0.01
CHRF 33.40 ± 0.00 104.52 ± 0.08
BURF 462.00 ± 0.00 193.02 ± 0.00
n-HRF 357.00 ± 0.00 123.06 ± 0.00
EARF 296.50 ± 0.00 53.55 ± 0.01
AQRF 28.00 ± 0.00 44.39 ± 0.00
Table 3. Influence of plant extracts or fractions of C. lutea upon HepG2 cell viability.
Extracts or fractions 0.1lg/mL 1lg/mL 10 lg/mL 100 lg/mL IC50 (lg/mL)
cETSE 101.20 ± 7.34 118.23 ± 9.23 121.34 ± 4.35 97.23 ± 2.34 > 2000
EASF 105.60 ± 10.24 102.40 ± 9.26 95.60 ± 7.25 35.5 ± 12.24 754
n-HSF oil 99.80 ± 11.25 103.20 ± 9.35 115.43 ± 7.36 93.23 ± 8.35 >2000
n-HSF 101.30 ± 8.35 113.54 ± 13.24 74.30 ± 8.35 46.2 ± 5.36 895
MTSF 105.60 ± 7.24 130.30 ± 12.13 112.20 ± 12.34 97.56 ± 10.23 >2000
MTSF oil 105.40 ± 6.35 113.50 ± 6.35 110.60 ± 9.39 95.65 ± 9.34 >2000
DCSF 107.50 ± 6.45 103.40 ± 7.35 98.50 ± 10.24 42.34 ± 8.34 843
cETSE oil 87.13 ± 8.34 79.23 ± 5.54 64.82 ± 4.35 56.20 ± 3.34 1010
HASE 101.23 ± 11.32 99.65 ± 6.34 91.26 ± 9.45 85.45 ± 8.36 >2000
cBULE 108.15 ± 0.57 110.72 ± 3.64 112.49 ± 3.14 73.39 ± 7.49 >2000
cEALE 102.87 ± 5.06 94.85 ± 1.19 104.89 ± 4.36 89.13 ± 5.29 >2000
cHALE 99.34 ± 12.23 98.12 ± 10.32 78.34 ± 8.34 61.23 ± 10.2 >2000
cMTRE 101.23 ± 9.24 123.20 ± 8.65 112.48 ± 5.34 99.50 ± 12.34 >2000
CHRF 99.30 ± 9.35 92.35 ± 10.23 82.50 ± 12.23 32.14 ± 10.24 691
EARF 101.70 ± 8.24 112.64 ± 6.45 122.40 ± 7.35 95.23 ± 13.23 >2000
Hep G2 cells were incubated with plant extracts or fractions at the concentrations specified for 48 h and the percentage of viable cells determined
using a MTT assay. Extract or fraction was assessed at least in triplicate across a 0.1–100 lg/mL concentration range, and an approximate IC50 calcu-
lated. For marked significance from controls,p< 0.05,p< 0.01,p< 0.001.
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may not normally be needed for acetylcholine hydrolysis since
BChE-deficient mice are healthy, and similarly, humans with no
BChE activity do not display signs of ill-health, or a loss of fertil-
ity or longevity (Manoharan et al. 2007; Lockridge 2015). BChE
may certainly substitute for AChE upon requirement since AChE
knockout mice are also viable (Mesulam et al. 2002), but the
importance of anti-BChE activity in AD drug development will
need further substantiation; and so the ability of C. lutea to
inhibit BChE has not yet been investigated further.
A recent in vivo study by Ajiwhen and Bisong (2013) admin-
istered a low-dose (1500mg/kg p.o.) of C. lutea root extract to
mice and reported cognitive memory enhancing activity, and this
may reflect the potent anti-AChE activity described herein. At
this dose of C. lutea roots, no toxicity to mice was reported
(Ajiwhen and Bisong 2013), and our in vitro study suggests that
at levels producing AChE inhibition (0.1–1 lg/mL), the majority
of C. lutea extracts/fractions are not toxic to human liver cells
(Table 3).
Carpolobia lutea possesses flavonoids (Table 2): polyphenols
that include flavones and isoflavones that are notable anti-AChE
inhibitors (Uriarte-Pueyo and Calvo 2011; Pinho et al. 2013).
However, there was not a direct correlation between total flavon-
oid levels in either stem, leaf or roots with corresponding anti-
AChE inhibitory potency (Table 1). Thus, we cannot yet com-
ment on the active agent that produces AChE inhibition, but
similar to other studies (Mukherjee et al. 2007; Calderon et al.
2010; S¸enol et al. 2010; Hlila et al. 2013; Natarajan et al. 2013;
Syad and Devi 2014), initial screening provides a means to identify
fractions suitable for further purification and active agent identifi-
cation. Thus, C. lutea remains a potentially beneficial pharmaco-
therapy that could be further developed for the treatment of AD
and/or other diseases such as Parkinson’s and myasthenia gravis
that also require agents able to address cholinergic deficits.
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